Alison (Ali) Turner

I joined the Project Management team in the Pandemic Sciences Institute (PSI) in May 2025.

I am engaged as Project Manager on two projects:

1) A multi-site, CEPI-funded project "Pre-clinical investigations into vaccine induced thrombosis with thrombocytopaenia" lead by Professor Dame Sarah Gilbert in collaboration with scientists at the PSI; the Children's Hospital of Philadelphia (CHOP); Cambridge Stem Cell Institute and Oxford Protein Informatics Group (OPIG).

2) A multi-site Wellcome Trust/CEPI project "​Characterisation of rapid onset protection after Nipah vaccination, and the influence of prior paramyxovirus exposure on reactivity to Nipah" lead by Professor Dame Sarah Gilbert in collaboration with scientists at the PSI; Oxford Vaccine Group (OVG); Big Data Institute (BDI) and the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B).

I have joined the PSI from Barinthus Biotherapeutics Ltd where I was most recently a Project Officer (working on MERS, HBV and Coeliac disease therapeutic programmes), and prior to that Director, Vector Production (manufacturing). 

Previously, I managed the Viral Vector Core Facility at the Jenner Institute, Oxford University for ten years producing over 3000 viral vectored vaccines for preclinical use by researchers at the Jenner Institute. 

I obtained my DPhil. from Oxford University studying T cell co-stimulation. During my career in bioscience have worked in several other Biotech companies (ProImmune Ltd, Oxxon Therapeutics and Medigene) as well as academic groups within Oxford University.